<p>HBK Sorce Advisory LLC 在最近向证券交易委员会提交的文件中表示，在第三季度收购了 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 免费报告) 的新股份。这家机构投资者购买了 76,408 股该生物技术公司的股票，价值约为 2,823,000 美元。截至最近一个季度末，HBK Sorce Advisory LLC 拥有 Arrowhead Pharmaceuticals 约 0.06% 的股份。</p>
<ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。Resona Asset Management Co. Ltd. 在第二季度将其在 Arrowhead Pharmaceuticals 的持股比例提高了 8.7%。Resona Asset Management Co. Ltd. 现在拥有 11,218 股该生物技术公司的股票，价值为 180,000 美元，此前在上个季度又购买了 900 股。Empowered Funds LLC 在第一季度将其在 Arrowhead Pharmaceuticals 的持股提高了 6.9%。Empowered Funds LLC 现在拥有 15,252 股该生物技术公司的股票，价值为 194,000 美元，此前在上个季度又购买了 979 股。GAMMA Investing LLC 在第三季度将其在 Arrowhead Pharmaceuticals 的持股提高了 64.4%。GAMMA Investing LLC 现在拥有 2,626 股该生物技术公司的股票，价值为 91,000 美元，此前在上个季度又购买了 1,029 股。KLP Kapitalforvaltning AS 在第二季度将其在 Arrowhead Pharmaceuticals 的持股提高了 5.2%。KLP Kapitalforvaltning AS 现在拥有 24,300 股该生物技术公司的股票，价值为 384,000 美元，此前在上个季度又购买了 1,200 股。最后，Mirae Asset Global Investments Co. Ltd. 在第二季度将其在 Arrowhead Pharmaceuticals 的持股提高了 29.5%。Mirae Asset Global Investments Co. Ltd. 现在拥有 5,335 股该生物技术公司的股票，价值为 84,000 美元，此前在上个季度又购买了 1,214 股。62.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Arrowhead Pharmaceuticals 价格表现</h2>
<p>ARWR 周三开盘价为 69.83 美元。该公司的流动比率为 4.86，速动比率为 4.86，债务与股本比率为 0.43。该股票的市值为 94.9 亿美元，市盈率为-872.77，贝塔值为 1.28。该股票的 50 日移动平均价格为 49.81 美元，200 日移动平均价格为 32.05 美元。Arrowhead Pharmaceuticals, Inc. 的 12 个月低点为 9.57 美元，12 个月高点为 72.36 美元。</p>
<h2>Arrowhead Pharmaceuticals 新闻摘要</h2>
<p>以下是本周影响 Arrowhead Pharmaceuticals 的主要新闻：</p>
<ul>
<li>积极情绪：公司计划在 1 月份进行的投资者活动可能成为近期催化剂：1 月 6 日的 KOL 网络研讨会将展示肥胖项目 ARO‑INHBE 和 ARO‑ALK7 的中期临床数据，以及 1 月 12 日在摩根大通医疗会议上的演讲。积极的中期数据或受到好评的 JPM 演讲可能会提升市场情绪。Arrowhead Pharmaceuticals 将参与即将于 2026 年 1 月举行的活动。</li>
<li>中性情绪：今天的交易活动低于该股票的平均交易量，这可能会抑制短期波动；基本面资产负债表指标依然强劲（高流动比率/速动比率）。没有发布公司指引或重大交易。</li>
<li>消极情绪：多位内部人士在 12 月底出售了股票——包括首席执行官 Christopher Anzalone 和几位董事——在 SEC 文件中披露并被媒体报道。内部人士的出售可能会被一些投资者解读为负面，尽管首席执行官仍持有大量股份（数百万股），且报告的减持在持股比例上变化不大。有关详细信息，请参见 SEC 文件和媒体报道。首席执行官 Form 4 董事 Form 4 董事 Form 4 董事 Form 4 媒体：内部人士出售</li>
</ul>
<h2>分析师评级变动</h2>
<p>ARWR 已成为多份分析师报告的主题。美国银行在 12 月 9 日的报告中将 Arrowhead Pharmaceuticals 的目标价从 62.00 美元上调至 81.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Arrowhead Pharmaceuticals 的 “卖出（d-）” 评级。Chardan Capital 在 12 月 1 日的研究报告中重申了 “买入” 评级，并设定了 60.00 美元的目标价。摩根士丹利在 11 月 26 日的研究报告中将 Arrowhead Pharmaceuticals 的目标价从 45.00 美元上调至 48.00 美元，并给予该股票 “持平” 评级。最后，加拿大皇家银行在 12 月 11 日的研究报告中将 Arrowhead Pharmaceuticals 的目标价从 52.00 美元上调至 80.00 美元，并给予该公司 “跑赢大盘” 评级。两位股票研究分析师对该股票给予了强烈买入评级，五位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Arrowhead Pharmaceuticals 目前的共识评级为 “适度买入”，共识目标价为 61.89 美元。</p>
<p><strong>查看我们关于 ARWR 的最新研究报告</strong></p>
<h2>Arrowhead Pharmaceuticals 的内部交易</h2>
<p>在关于箭头制药的其他消息中，董事 Adeoye Y. Olukotun 于 12 月 19 日星期五出售了 10,000 股公司的股票。股票以平均价格 67.66 美元出售，总交易额为 676,600.00 美元。交易完成后，该董事直接持有 33,600 股公司股票，价值 2,273,376 美元。这代表其持股比例下降了 22.94%。该交易已在向 SEC 提交的文件中披露，具体信息可通过此链接查看。此外，董事 William D. Waddill 于 12 月 19 日星期五出售了 8,367 股箭头制药的股票。股票以平均价格 67.65 美元出售，总价值为 566,027.55 美元。交易完成后，该董事持有 56,563 股公司股票，价值约为 3,826,486.95 美元。这代表其持股比例下降了 12.89%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士出售了 368,736 股公司股票，价值 23,670,228 美元。公司内部人士持有 4.30% 的公司股票。</p>
<h2>关于箭头制药</h2>
<p>(免费报告)</p>
<p>箭头制药公司是一家临床阶段的生物制药公司，专注于 RNA 干扰（RNAi）治疗的发现、开发和商业化。自 2008 年成立以来，箭头制药利用其专有的递送平台——内部称为先进 RNAi 化合物（ARC）技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久的、针对性的治疗，涵盖多个治疗领域。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过箭头制药</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解析</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [不是 NVDA]</li>
<li>特朗普做了什么？？</li>
<li>崩盘前一个月</li>
</ul>
<p><strong>想看看其他对 ARWR 感兴趣的对冲基金持有什么？</strong> 访问 HoldingsChannel.com，获取箭头制药公司（NASDAQ:ARWR - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于箭头制药吗？</h2>
<p>在考虑箭头制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而箭头制药并不在名单上。</p>
<p>虽然箭头制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

<p>HBK Sorce Advisory LLC 在第三季度收购了 76,408 股箭头制药，价值约为 282 万美元。这次收购代表了该公司约 0.06% 的股份。其他机构投资者也对箭头制药的持仓进行了调整。该股票的表现和分析师评级显示出混合的情绪，部分分析师持积极展望，同时也注意到内部人士的减持</p>

<p>HBK Sorce Advisory LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor acquired 76,408 shares of the biotechnology company's stock, valued at approximately $2,823,000. HBK Sorce Advisory LLC owned about 0.06% of Arrowhead Pharmaceuticals at the end of the most recent quarter.</p>
<div class="lb-trans"><p>HBK Sorce Advisory LLC 在最近向证券交易委员会提交的文件中表示，在第三季度收购了 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 免费报告) 的新股份。这家机构投资者购买了 76,408 股该生物技术公司的股票，价值约为 2,823,000 美元。截至最近一个季度末，HBK Sorce Advisory LLC 拥有 Arrowhead Pharmaceuticals 约 0.06% 的股份。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Resona Asset Management Co. Ltd. lifted its position in shares of Arrowhead Pharmaceuticals by 8.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company's stock valued at $180,000 after buying an additional 900 shares during the last quarter. Empowered Funds LLC lifted its holdings in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after purchasing an additional 979 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Arrowhead Pharmaceuticals by 64.4% during the third quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company's stock valued at $91,000 after purchasing an additional 1,029 shares during the last quarter. KLP Kapitalforvaltning AS increased its stake in shares of Arrowhead Pharmaceuticals by 5.2% in the second quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company's stock worth $384,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 1,214 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。Resona Asset Management Co. Ltd. 在第二季度将其在 Arrowhead Pharmaceuticals 的持股比例提高了 8.7%。Resona Asset Management Co. Ltd. 现在拥有 11,218 股该生物技术公司的股票，价值为 180,000 美元，此前在上个季度又购买了 900 股。Empowered Funds LLC 在第一季度将其在 Arrowhead Pharmaceuticals 的持股提高了 6.9%。Empowered Funds LLC 现在拥有 15,252 股该生物技术公司的股票，价值为 194,000 美元，此前在上个季度又购买了 979 股。GAMMA Investing LLC 在第三季度将其在 Arrowhead Pharmaceuticals 的持股提高了 64.4%。GAMMA Investing LLC 现在拥有 2,626 股该生物技术公司的股票，价值为 91,000 美元，此前在上个季度又购买了 1,029 股。KLP Kapitalforvaltning AS 在第二季度将其在 Arrowhead Pharmaceuticals 的持股提高了 5.2%。KLP Kapitalforvaltning AS 现在拥有 24,300 股该生物技术公司的股票，价值为 384,000 美元，此前在上个季度又购买了 1,200 股。最后，Mirae Asset Global Investments Co. Ltd. 在第二季度将其在 Arrowhead Pharmaceuticals 的持股提高了 29.5%。Mirae Asset Global Investments Co. Ltd. 现在拥有 5,335 股该生物技术公司的股票，价值为 84,000 美元，此前在上个季度又购买了 1,214 股。62.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Arrowhead Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 价格表现</h2>
</div><p>ARWR opened at $69.83 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. The stock has a 50-day moving average price of $49.81 and a 200-day moving average price of $32.05. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36.</p>
<div class="lb-trans"><p>ARWR 周三开盘价为 69.83 美元。该公司的流动比率为 4.86，速动比率为 4.86，债务与股本比率为 0.43。该股票的市值为 94.9 亿美元，市盈率为-872.77，贝塔值为 1.28。该股票的 50 日移动平均价格为 49.81 美元，200 日移动平均价格为 32.05 美元。Arrowhead Pharmaceuticals, Inc. 的 12 个月低点为 9.57 美元，12 个月高点为 72.36 美元。</p>
</div><h2>Arrowhead Pharmaceuticals News Summary</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 新闻摘要</h2>
</div><p>Here are the key news stories impacting Arrowhead Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响 Arrowhead Pharmaceuticals 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Company-scheduled investor activity in January could be a near-term catalyst: a KOL webinar on Jan 6 that will feature interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, plus a presentation at the J.P. Morgan Healthcare Conference on Jan 12. Favorable interim data or a well-received JPM presentation could boost sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events</li>
<li>Neutral Sentiment: Trading activity is below the stock’s average volume today, which can mute short-term moves; fundamental balance-sheet metrics remain strong (high current/quick ratios). No corporate guidance or major deals were announced.</li>
<li>Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC filings and covered by press. Insider sales can be interpreted negatively by some investors even though the CEO retains a very large position (millions of shares) and reported reductions were small percentage changes in holdings. See SEC filings and press coverage for details. CEO Form 4Director Form 4Director Form 4Director Form 4Press: Insider Selling</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：公司计划在 1 月份进行的投资者活动可能成为近期催化剂：1 月 6 日的 KOL 网络研讨会将展示肥胖项目 ARO‑INHBE 和 ARO‑ALK7 的中期临床数据，以及 1 月 12 日在摩根大通医疗会议上的演讲。积极的中期数据或受到好评的 JPM 演讲可能会提升市场情绪。Arrowhead Pharmaceuticals 将参与即将于 2026 年 1 月举行的活动。</li>
<li>中性情绪：今天的交易活动低于该股票的平均交易量，这可能会抑制短期波动；基本面资产负债表指标依然强劲（高流动比率/速动比率）。没有发布公司指引或重大交易。</li>
<li>消极情绪：多位内部人士在 12 月底出售了股票——包括首席执行官 Christopher Anzalone 和几位董事——在 SEC 文件中披露并被媒体报道。内部人士的出售可能会被一些投资者解读为负面，尽管首席执行官仍持有大量股份（数百万股），且报告的减持在持股比例上变化不大。有关详细信息，请参见 SEC 文件和媒体报道。首席执行官 Form 4 董事 Form 4 董事 Form 4 董事 Form 4 媒体：内部人士出售</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>ARWR has been the subject of several analyst reports. Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, December 9th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, November 26th. Finally, Royal Bank Of Canada upped their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $61.89.</p>
<div class="lb-trans"><p>ARWR 已成为多份分析师报告的主题。美国银行在 12 月 9 日的报告中将 Arrowhead Pharmaceuticals 的目标价从 62.00 美元上调至 81.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Arrowhead Pharmaceuticals 的 “卖出（d-）” 评级。Chardan Capital 在 12 月 1 日的研究报告中重申了 “买入” 评级，并设定了 60.00 美元的目标价。摩根士丹利在 11 月 26 日的研究报告中将 Arrowhead Pharmaceuticals 的目标价从 45.00 美元上调至 48.00 美元，并给予该股票 “持平” 评级。最后，加拿大皇家银行在 12 月 11 日的研究报告中将 Arrowhead Pharmaceuticals 的目标价从 52.00 美元上调至 80.00 美元，并给予该公司 “跑赢大盘” 评级。两位股票研究分析师对该股票给予了强烈买入评级，五位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Arrowhead Pharmaceuticals 目前的共识评级为 “适度买入”，共识目标价为 61.89 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ARWR</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ARWR 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 的内部交易</h2>
</div><p>In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the company's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the sale, the director directly owned 33,600 shares in the company, valued at $2,273,376. This represents a 22.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 8,367 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $67.65, for a total value of $566,027.55. Following the completion of the transaction, the director owned 56,563 shares in the company, valued at approximately $3,826,486.95. This represents a 12.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 368,736 shares of company stock worth $23,670,228. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在关于箭头制药的其他消息中，董事 Adeoye Y. Olukotun 于 12 月 19 日星期五出售了 10,000 股公司的股票。股票以平均价格 67.66 美元出售，总交易额为 676,600.00 美元。交易完成后，该董事直接持有 33,600 股公司股票，价值 2,273,376 美元。这代表其持股比例下降了 22.94%。该交易已在向 SEC 提交的文件中披露，具体信息可通过此链接查看。此外，董事 William D. Waddill 于 12 月 19 日星期五出售了 8,367 股箭头制药的股票。股票以平均价格 67.65 美元出售，总价值为 566,027.55 美元。交易完成后，该董事持有 56,563 股公司股票，价值约为 3,826,486.95 美元。这代表其持股比例下降了 12.89%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士出售了 368,736 股公司股票，价值 23,670,228 美元。公司内部人士持有 4.30% 的公司股票。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于箭头制药</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>箭头制药公司是一家临床阶段的生物制药公司，专注于 RNA 干扰（RNAi）治疗的发现、开发和商业化。自 2008 年成立以来，箭头制药利用其专有的递送平台——内部称为先进 RNAi 化合物（ARC）技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久的、针对性的治疗，涵盖多个治疗领域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Trump Did WHAT??</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过箭头制药</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解析</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [不是 NVDA]</li>
<li>特朗普做了什么？？</li>
<li>崩盘前一个月</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ARWR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ARWR 感兴趣的对冲基金持有什么？</strong> 访问 HoldingsChannel.com，获取箭头制药公司（NASDAQ:ARWR - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于箭头制药吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑箭头制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而箭头制药并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然箭头制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HBK Sorce Advisory LLC 收购了箭头制药（Arrowhead Pharmaceuticals, Inc.）76,408 股股票